CDRE vs. ENOV, ESTA, AVNS, ZJYL, SMTI, INGN, LAKE, CLGN, NTRB, and APT
Should you be buying Cadre stock or one of its competitors? The main competitors of Cadre include Enovis (ENOV), Establishment Labs (ESTA), Avanos Medical (AVNS), Jin Medical International (ZJYL), Sanara MedTech (SMTI), Inogen (INGN), Lakeland Industries (LAKE), CollPlant Biotechnologies (CLGN), Nutriband (NTRB), and Alpha Pro Tech (APT). These companies are all part of the "surgical appliances & supplies" industry.
Enovis (NYSE:ENOV) and Cadre (NYSE:CDRE) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their analyst recommendations, risk, community ranking, dividends, valuation, earnings, media sentiment, institutional ownership and profitability.
Enovis currently has a consensus price target of $75.43, indicating a potential upside of 62.74%. Cadre has a consensus price target of $41.25, indicating a potential upside of 27.16%. Given Cadre's stronger consensus rating and higher probable upside, analysts plainly believe Enovis is more favorable than Cadre.
In the previous week, Enovis had 1 more articles in the media than Cadre. MarketBeat recorded 2 mentions for Enovis and 1 mentions for Cadre. Cadre's average media sentiment score of 1.95 beat Enovis' score of 0.00 indicating that Enovis is being referred to more favorably in the media.
Cadre has lower revenue, but higher earnings than Enovis. Enovis is trading at a lower price-to-earnings ratio than Cadre, indicating that it is currently the more affordable of the two stocks.
Enovis received 9 more outperform votes than Cadre when rated by MarketBeat users. Likewise, 60.00% of users gave Enovis an outperform vote while only 53.57% of users gave Cadre an outperform vote.
Enovis has a beta of 1.94, indicating that its share price is 94% more volatile than the S&P 500. Comparatively, Cadre has a beta of 1.3, indicating that its share price is 30% more volatile than the S&P 500.
Cadre has a net margin of 7.58% compared to Cadre's net margin of -4.51%. Enovis' return on equity of 19.18% beat Cadre's return on equity.
98.5% of Enovis shares are held by institutional investors. Comparatively, 44.0% of Cadre shares are held by institutional investors. 2.4% of Enovis shares are held by company insiders. Comparatively, 49.2% of Cadre shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Summary
Enovis beats Cadre on 10 of the 18 factors compared between the two stocks.
Get Cadre News Delivered to You Automatically
Sign up to receive the latest news and ratings for CDRE and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CDRE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
